U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07336446) titled 'A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs' on Dec. 19, 2025.
Brief Summary: ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.
Study Start Date: Jan. 05
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DRUG: AZD9750
AR-PROTAC
DRUG: AZD5305
PARP1-selective in...